Pharmacokinetics of co-formulated mefloquine and artesunate in pregnant and non-pregnant women with uncomplicated Plasmodium falciparum infection in Burkina Faso

Journal of Antimicrobial Chemotherapy

Volumn 69, Issue 9, 2014, Pages 2499-2507

  Valea, Innocent ^a,b   Tinto, Halidou ^a,b   Coulibaly, Maminata Traore ^b   Toe, Laeticia C ^a   Lindegardh, Niklas ^c,d   Tarning, Joel ^c,d   Geertruyden, Jean Pierre Van ^e   D'Alessandro, Umberto ^f,g   Davies, Geraint R ^h   Ward, Stephen A ⁱ  

^a CENTRE MURAZ   (Burkina Faso)

^b Institut de Recherche en Sciences de la Santé   (Burkina Faso)

^c MAHIDOL UNIVERSITY   (Thailand)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e UNIVERSITY OF ANTWERP   (Belgium)

^f INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^g MEDICAL RESEARCH COUNCIL LABORATORIES   (Gambia)

^h UNIVERSITY OF LIVERPOOL   (United Kingdom)

ⁱ LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

Author keywords

Antimalarials; PK; Pregnancy

Indexed keywords

ANTIMALARIAL AGENT; ARTESUNATE; CARBOXYMEFLOQUINE; DIHYDROARTEMISININ; HEMOGLOBIN; MEFLOQUINE; UNCLASSIFIED DRUG; ARTEMISININ DERIVATIVE; DRUG COMBINATION;

ADULT; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; BURKINA FASO; CLINICAL ARTICLE; COUGHING; DIZZINESS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXPOSURE; DRUG FORMULATION; DRUG HALF LIFE; FEMALE; FOLLOW UP; HEADACHE; HEMOGLOBIN BLOOD LEVEL; HUMAN; INFECTION; MALARIA FALCIPARUM; MAXIMUM PLASMA CONCENTRATION; POLYDACTYLY; PREGNANT WOMAN; RECURRENT INFECTION; SECOND TRIMESTER PREGNANCY; THIRD TRIMESTER PREGNANCY; THROMBOCYTE COUNT; TIME TO MAXIMUM PLASMA CONCENTRATION; VOMITING; ADOLESCENT; CHEMISTRY; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG COMBINATION; MALARIA, FALCIPARUM; PLASMA; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIMALARIALS; ARTEMISININS; BURKINA FASO; DRUG COMBINATIONS; FEMALE; HUMANS; MALARIA, FALCIPARUM; MEFLOQUINE; PLASMA; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; YOUNG ADULT;

EID: 84905987915     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dku154     Document Type: Article

References (34)

1. Desai M, Ter Kuile FO, Nosten F et al. Epidemiology and burden of malaria in pregnancy. Lancet Infect Dis 2007; 7: 93-104.
2. Guyatt HL, Snow RW. The epidemiology and burden of Plasmodium falciparum-related anemia among pregnant women in sub-Saharan Africa. Am J Trop Med Hyg 2001; 64: 36-44.
3. Kayentao K, Mungai M, Parise M et al. Assessing malaria burden during pregnancy in Mali. Acta Trop 2007; 102: 106-12.
4. Brabin BJ. An analysis of malaria in pregnancy in Africa. BullWorld Health Organ 1983; 61: 1005-16.
5. Lagerberg RE. Malaria in pregnancy: a literature review. J Midwifery Womens Health 2008; 53: 209-15.
6. Tagbor H, Bruce J, Browne E et al. Malaria in pregnancy in an area of stable and intense transmission: is it asymptomatic? Trop Med Int Health 2008; 13: 1016-21.
7. Steketee RW, Nahlen BL, Parise ME et al. The burden of malaria in pregnancy in malaria-endemic areas. Am J Trop Med Hyg 2001; 64: 28-35.
8. Guthmann JP, Cohuet S, Rigutto C et al. High efficacy of two artemisininbased combinations (artesunate + amodiaquine and artemether + lumefantrine) in Caala, Central Angola. AmJ TropMed Hyg 2006; 75: 143-5.
9. WHO/AFRO. A Strategic Framework for Malaria Prevention and Control During Pregnancy in the African Region. Geneva: WHO, 2004.
10. Falade C, Makanga M, Premji Z et al. Efficacy and safety of artemetherlumefantrine (Coartem) tablets (six-dose regimen) in African infants and children with acute, uncomplicated falciparum malaria. Trans R Soc Trop Med Hyg 2005; 99: 459-67.
11. Nosten F, White NJ. Artemisinin-based combination treatment of falciparum malaria. Am J Trop Med Hyg 2007; 77: 181-92.
12. Mutabingwa TK, Anthony D, Heller A et al. Amodiaquine alone, amodiaquine+sulfadoxine-pyrimethamine, amodiaquine+artesunate, and artemether-lumefantrine for outpatient treatment of malaria in Tanzanian children: a four-arm randomised effectiveness trial. Lancet 2005; 365: 1474-80.
13. Dawes M, Chowienczyk PJ. Drugs in pregnancy. Pharmacokinetics in pregnancy. Best Pract Res Clin Obstet Gynaecol 2001; 15: 819-26.
14. Tarning J, McGready R, Lindegardh N et al. Population pharmacokinetics of lumefantrine in pregnant women treated with artemether-lumefantrine for uncomplicated Plasmodium falciparum malaria. Antimicrob Agents Chemother 2009; 53: 3837-46.
15. Tarning J, Rijken MJ, McGready R et al. Population pharmacokinetics of dihydroartemisinin and piperaquine in pregnant and nonpregnant women with uncomplicated malaria. Antimicrob Agents Chemother 2012; 56: 1997-2007.
16. Steketee RW, Wirima JJ, Slutsker L et al. Malaria parasite infection during pregnancy and at delivery in mother, placenta, and newborn: efficacy of chloroquine and mefloquine in rural Malawi. Am J Trop Med Hyg 1996; 55 Suppl: 24-32.
17. WHO. Guidelines for the Treatment of Malaria, Second Edition. Geneva: WHO, 2010.
18. Menéndez C, D'Alessandro U, Ter Kuile FO. Reducing the burden of malaria in pregnancy by preventive strategies. Lancet Infect Dis 2007; 7: 126-35.
19. Nosten F, Karbwang J, White NJ et al. Mefloquine antimalarial prophylaxis in pregnancy: dose finding and pharmacokinetic study. Br J Clin Pharmacol 1990; 30: 79-85.
20. Na BK, Davis TM, Looareesuwan S et al. Mefloquine pharmacokinetics in pregnant women with acute falciparum malaria. Trans R Soc Trop Med Hyg 1994; 88: 321-3.
21. Karbwang J, Na BK, Thanavibul A et al. Pharmacokinetics of mefloquine alone or in combination with artesunate. Bull World Health Organ 1994; 72: 83-7.
22. WHO. Methods and Techniques for Clinical Trials on Antimalarial Drug Efficacy: Genotyping to Identify Parasite Populations. Geneva: WHO, 2007.
23. Diourté Y, Djimdé A, Doumbo OK et al. Pyrimethamine and proguanil resistance-conferring mutations in Plasmodium falciparum dihydrofolate reductase: polymerase chain reaction methods for surveillance in Africa. Am J Trop Med Hyg 2005; 52: 475-8.
24. Hanpithakpong W, Kamanikom B, Dondorp AM et al. A liquid chromatographic-tandem mass spectrometric method for determination of artesunate and its metabolite dihydroartemisinin in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 2008; 876: 61-8.
25. Wilby KJ, Ensom MH. Pharmacokinetics of antimalarials in pregnancy: a systematic review. Clin Pharmacokinet 2011; 50: 705-23.
26. Onyamboko MA, Meshnick SR, Fleckenstein L et al. Pharmacokinetics and pharmacodynamics of artesunate and dihydroartemisinin following oral treatment in pregnant women with asymptomatic Plasmodium falciparum infections in Kinshasa DRC. Malar J 2011; 10: 49.
27. McGready R, Stepniewska K, Lindegardh N et al. The pharmacokinetics of artemether and lumefantrine in pregnant women with uncomplicated falciparum malaria. Eur J Clin Pharmacol 2006; 62: 1021-31.
28. Morris CA, Onyamboko MA, Capparelli E et al. Population pharmacokinetics of artesunate and dihydroartemisinin in pregnant and non-pregnant women with malaria. Malar J 2011; 10: 114.
29. Tarning J, Kloprogge F, Piola P et al. Population pharmacokinetics of Artemether and dihydroartemisinin in pregnant women with uncomplicated Plasmodium falciparum malaria in Uganda. Malar J 2012; 11: 293.
30. McGready R, Phyo AP, Rijken MJ et al. Artesunate/dihydroartemisinin pharmacokinetics in acute falciparum malaria in pregnancy: absorption, bioavailability, disposition and disease effects. Br J Clin Pharmacol 2012; 73: 467-77.
31. Ye XY, Shao BR, Chu YH. The blood schizontocidal effects of pyronaridine, amodiaquine, mefloquine and qinghaosu on mice infected with Plasmodium berghei. Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi 1992; 10: 120-3.
32. Bukirwa H, Orton L. Artesunate plus mefloquine versus mefloquine for treating uncomplicated malaria. Cochrane Database Syst Rev 2005; issue 4: CD004531.
33. Briand V, Denoeud L, Massougbodji A, Cot M. Efficacy of intermittent preventive treatment versus chloroquine prophylaxis to prevent malaria during pregnancy in Benin. J Infect Dis 2008; 198: 594-601.
34. Schlagenhauf P, Blumentals WA, Suter P et al. Pregnancy and fetal outcomes after exposure to mefloquine in the pre- and periconception period and during pregnancy. Clin Infect Dis 2012; 54: e124-31.